Development of oseltamivir and zanamivir resistance in influenza a(H1N1)pdm09 virus, Denmark, 2014

Eurosurveillance

Volumn 22, Issue 3, 2017, Pages

  Trebbien, Ramona ^a   Pedersen, S S ^b   Vorborg, K ^a   Franck, K T ^a,c   Fischer, T K ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ADULT; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DENMARK; DISEASE TRANSMISSION; DRUG SENSITIVITY; ENZYME INHIBITION ASSAY; GENOTYPE; HUMAN; IC50; IMMUNOCOMPROMISED PATIENT; INFLUENZA A; NASOPHARYNGEAL ASPIRATION; NEXT GENERATION SEQUENCING; PHENOTYPE; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE CULTURE INFECTIVE DOSE 50; VACCINATION; VIRUS CONCENTRATION; VIRUS DETECTION; VIRUS ISOLATION; VIRUS LOAD; ANTIVIRAL RESISTANCE; COMPLICATION; DRUG EFFECTS; GENETICS; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DENMARK; DRUG RESISTANCE, VIRAL; GENOTYPE; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MUTATION; NEURAMINIDASE; OSELTAMIVIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; ZANAMIVIR;

EID: 85010703043     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2017.22.3.30445     Document Type: Article

References (28)

1. LeGoff J, Rousset D, Abou-Jaoudé G, Scemla A, Ribaud P, Mercier-Delarue S, et al. I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y. PLoS One. 2012;7(8):e37095. DOI: 10.1371/journal.pone.0037095 PMID: 22936969
2. Alonso M, Rodríguez-Sánchez B, Giannella M, Catalán P, Gayoso J, Lopez Bernaldo de Quirós JC, et al. Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. J Clin Virol. 2011;50(2):114-8. DOI: 10.1016/j.jcv.2010.10.007 PMID: 21074490
3. Bruminhent J, Deziel PJ, Wotton JT, Binnicker MJ, Razonable RR. Prolonged shedding of pandemic influenza A (H1N1) 2009 virus in a pancreas-after-kidney transplant recipient. J Clin Virol. 2014;61(2):302-4. DOI: 10.1016/j.jcv.2014.07.004 PMID: 25081940
4. Gooskens J, Jonges M, Claas ECJ, Meijer A, Kroes ACM. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis. 2009;199(10):1435-41. DOI: 10.1086/598684 PMID: 19392620
5. World Health Organization (WHO). Influenza Vaccines. Geneva: WHO. [Accessed 20 May 2016]. Available at: http://www.who.int/influenza/vaccines/en/
6. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2014-15 northern hemisphere influenza season. Geneva: WHO. [Accessed 20 May 2016]. Available at: http://www.who.int/influenza/vaccines/virus/recommendations/201402_recommendation.pdf?ua=1
7. O’Shea D, Widmer LA, Stelling J, Egli A. Changing face of vaccination in immunocompromised hosts. Curr Infect Dis Rep. 2014;16(9):420. DOI: 10.1007/s11908-014-0420-2 PMID: 24992978
8. Zbinden D, Manuel O. Influenza vaccination in immunocompromised patients: efficacy and safety. Immunotherapy. 2014;6(2):131-9. DOI: 10.2217/imt.13.171 PMID: 24491087
9. Ison MG. Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respi Viruses. 2013;7(Suppl 3):60-6. DOI: 10.1111/irv.12170 PMID: 24215383
10. Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2013;10(10):CD008983.PMID: 24166741
11. Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, et al. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. Influenza Other Respi Viruses. 2013;7(Suppl 2):72-5. DOI: 10.1111/irv.12084 PMID: 24034488
12. van der Velden AMT, Mulder AHL, Hartkamp A, Diepersloot RJA, van Velzen-Blad H, Biesma DH. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med. 2001;12(5):420-4. DOI: 10.1016/S0953-6205(01)00149-2 PMID: 11557327
13. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366(9492):1175-81. DOI: 10.1016/S0140-6736(05)67338-2 PMID: 16198766
14. Dong G, Peng C, Luo J, Wang C, Han L, Wu B, et al. Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations. PLoS One. 2015;10(3):e0119115. DOI: 10.1371/journal.pone.0119115 PMID: 25768797
15. Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014;8(0):22-9. DOI: 10.1016/j.coviro.2014.04.009 PMID: 24866471
16. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012;17(1 Pt B):159-73. DOI: 10.3851/IMP2067 PMID: 22311680
17. Pozo F, Lina B, Andrade HR, Enouf V, Kossyvakis A, Broberg E, et al. Community Network of Reference Laboratories for Human Influenza in Europe. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe.J Clin Virol. 2013;57(1):5-12. DOI: 10.1016/j.jcv.2013.01.009 PMID: 23375738
18. Takashita E, Fujisaki S, Shirakura M, Nakamura K, Kishida N, Kuwahara T, et al. Influenza Virus Surveillance Group of Japan. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016.Euro Surveill. 2016;21(24):30258. DOI: 10.2807/1560-7917.ES.2016.21.24.30258 PMID: 27336226
19. World Health Organization (WHO) Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO press; 2011.
20. World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012.Wkly Epidemiol Rec. 2012;87(39):369-74.PMID: 23061103
21. Ives JAL, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002;55(2):307-17. DOI: 10.1016/S0166-3542(02)00053-0 PMID: 12103431
22. Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, et al. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrob Agents Chemother. 2012;56(3):1208-14. DOI: 10.1128/AAC.05994-11 PMID: 22203589
23. Tramontana AR, George B, Hurt AC, Doyle JS, Langan K, Reid AB, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis. 2010;16(7):1068-75. DOI: 10.3201/eid1607.091691 PMID: 20587176
24. European Centre for Disease Prevention and Control (ECDC)/WHO Regional Office for Europe. Flu News Europe, Joint ECDC–WHO weekly influenza update, week 20/2015. ECDC–WHO; 2015.
25. Correia V, Santos LA, Gíria M, Almeida-Santos MM, Rebelo-de-Andrade H. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs. J Med Virol. 2015;87(1):45-56. DOI: 10.1002/jmv.23986 PMID: 25042157
26. Rogers MB, Song T, Sebra R, Greenbaum BD, Hamelin M-E, Fitch A, et al. Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection. MBio. 2015;6(2):e02464-14. DOI: 10.1128/mBio.02464-14 PMID: 25852163
27. To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50(6):850-9. DOI: 10.1086/650581 PMID: 20136415
28. Zhirnov OP, Vorobjeva IV, Saphonova OA, Poyarkov SV, Ovcharenko AV, Anhlan D, et al. Structural and evolutionary characteristics of HA, NA, NS and M genes of clinical influenza A/H3N2 viruses passaged in human and canine cells. J Clin Virol. 2009;45(4):322-33. DOI: 10.1016/j.jcv.2009.05.030 PMID: 19546028